R R

What Is Retatrutide?

Retatrutide is an investigational medication being developed by Eli Lilly for obesity and certain related metabolic conditions. It is a single molecule that activates three hormone receptors associated with glucose regulation, appetite, and energy metabolism. These are the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. Retatrutide is administered by subcutaneous injection in clinical trials. As of November 2026, it has not received FDA approval and is not legally marketed for human use. Researchers are evaluating its effects on body weight, metabolic outcomes, and long-term safety through Phase 3 studies.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Retatrutide?

Retatrutide is an investigational medication being developed by Eli Lilly for obesity and certain related metabolic conditions. It is a single molecule that activates three hormone receptors associated with glucose regulation, appetite, and energy metabolism. These are the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. Retatrutide is administered by subcutaneous injection in clinical trials. As of November 2026, it has not received FDA approval and is not legally marketed for human use. Researchers are evaluating its effects on body weight, metabolic outcomes, and long-term safety through Phase 3 studies.

read more about retatrutide ...

Copy this HTML:

Copy HTML Copied!

How Does Retatrutide Work?

Retatrutide activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. These hormones participate in appetite regulation, glucose metabolism, and energy balance through overlapping but distinct pathways. GLP-1 and GIP receptor activity can influence insulin secretion and food intake, while glucagon receptor activity may contribute to changes in energy expenditure and metabolism. Combining these actions in one investigational medication is intended to produce meaningful metabolic effects. The precise contribution of each receptor pathway to clinical results remains under investigation. Retatrutide is not interchangeable with approved GLP-1 receptor agonists or other weight-management medications.

What Conditions Is Retatrutide Being Studied For?

Retatrutide is being evaluated in clinical trials involving adults with obesity or overweight and selected weight-related medical conditions. Research has examined changes in body weight, glucose regulation, and other metabolic outcomes. Clinical development also includes studies involving conditions associated with excess body weight and metabolic dysfunction. Early and later-stage research has reported substantial average weight reductions in certain study populations, but these findings do not establish an FDA-approved indication. Trial results must be evaluated alongside adverse events and longer-term outcomes. Retatrutide should not be described as an approved treatment for obesity, diabetes, or another medical condition.

How Is Retatrutide Administered in Clinical Trials?

Retatrutide is administered by subcutaneous injection once weekly in clinical trials. Investigators have evaluated different dose levels and gradual dose-escalation schedules to assess treatment response and tolerability. Some published studies have included maintenance doses as high as 12 mg weekly, but research regimens are not approved prescribing instructions. There is no FDA-approved therapeutic dose, commercially authorized formulation, or routine patient administration schedule. Retatrutide should be obtained only through legitimate, authorized clinical research participation. Products advertised online as retatrutide for personal use may have unverified ingredients, incorrect concentrations, or contamination risks.

What Are the Side Effects and Warnings of Retatrutide?

Clinical studies have reported gastrointestinal adverse effects, including nausea, vomiting, diarrhea, and constipation. These reactions can be more noticeable during dose escalation. Increases in heart rate and other treatment-related findings have also been evaluated. Because retatrutide remains investigational, its complete safety profile, long-term risks, and potential medication interactions have not been established through the regulatory approval process. Safety concerns associated with illicit products include uncertain identity, dosing errors, and contamination. Patients should not use unapproved retatrutide products for self-treatment. Anyone considering clinical trial participation should discuss eligibility, potential adverse effects, and monitoring requirements with the research team.

Common Questions About Retatrutide

Is retatrutide FDA-approved?

No. As of November 3, 2026, retatrutide remains investigational and has not received FDA approval.

Is retatrutide a GLP-1 medication?

Retatrutide activates GLP-1 receptors, but it also activates GIP and glucagon receptors. It is classified as an investigational triple receptor agonist.

How often is retatrutide given in clinical studies?

Retatrutide has been administered by subcutaneous injection once weekly in clinical trials. There is no approved dosing schedule for routine medical use.

Can retatrutide be purchased legally for personal treatment?

No. Retatrutide is not approved or legally marketed for human use. Products sold outside authorized research settings should not be assumed safe or genuine.

References

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05929066. Date Accessed November 3, 2026.

Efficacy and Safety of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, in People With Type 2 Diabetes and Inadequate Glycaemic Control With Diet and Exercise (TRANSCEND-T2D-1): A Double-Blind, Randomised, Phase 3 Trial. The Lancet. https://pubmed.ncbi.nlm.nih.gov/42250575/. Date Accessed November 3, 2026.

Retatrutide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Retatrutide. Date Accessed November 3, 2026.

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2604169. Date Accessed November 3, 2026.

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972. Date Accessed November 3, 2026.